Home/Pipeline/Myeloma and Solid Tumors

Myeloma and Solid Tumors

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

Vichem Chemie Research

About Vichem Chemie Research

Vichem Chemie Research is a Budapest-based, private contract research organization (CRO) and drug discovery company with a 30+ year history. Its core business model combines fee-for-service chemistry and biology work with the development of its own proprietary chemical libraries and internal therapeutic programs, primarily focused on kinase inhibitors. The company leverages strategic alliances and has received grant funding from Hungarian and European sources, indicating a hybrid revenue model of services and grants while advancing its pipeline.

View full company profile

Therapeutic Areas

Oncology Virology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active